Liquidity risk
The company relies on ongoing sales, grants, and funding to support operations before scale is reached.
- Scope
- If budgeted sales are not achieved, liquidity pressure may emerge.
- Materiality
- high
AcouSort
AcouSort is a Swedish medical technology company that develops acoustofluidic sample-preparation systems and OEM components for life science instrumentation. Its products are used to automate the handling, separation, washing, trapping, and preparation of biological samples in diagnostics, cell therapy, and laboratory workflows.
| % | |
|---|---|
| OEM components | 45% Acoustofluidic modules and components embedded into third-party diagnostic and therapeutic instruments. |
| Research and innovation systems | 30% Benchtop AcouWash and AcouTrap systems used for evaluation, development, and workflow validation. |
| License fees | 15% Technology licensing and related rights tied to use of AcouSort's platform. |
| Product sales and services | 10% Sales of systems, kits, and technical services supporting customer integration projects. |
AcouSort sells primarily to life science instrument manufacturers that want to embed automated sample-preparation steps...
- Life science OEMsprimary
Buy OEM components and integration support to embed automated sample processing into instruments.
- Cell therapy developersprimary
Use the technology to automate cell washing, separation, and handling in manufacturing workflows.
- Diagnostics companiesprimary
Evaluate AcouSort's platform for blood, plasma, and cell-processing steps in diagnostic systems.
- Research institutionssecondary
Buy benchtop systems and evaluation kits for scientific studies and workflow validation.
- Industrial manufacturersemerging
Explore particle-removal and process-integration use cases in production workflows.
AcouSort is headquartered in Sweden and serves customers across North America, Europe, and selected markets in Asia...
- •Sweden is the corporate base and operating center
- •North America is supported through AcouSort Inc. in the U.S.
- •Europe is a core market for OEM and research collaborations
- •Asia is part of the company's expanding commercial footprint
- •International sales depend on partner adoption and local validation
AcouSort's strategy is to convert its acoustofluidics platform from technology validation into broader OEM adoption and...
01
OEM-driven commercializationshort-term
Embedded components can create repeatable revenue and deeper customer integration.
02
Convert feasibility work into long-term agreementsmedium-term
Pilot projects are the main route to scaled adoption in regulated life science workflows.
03
Broaden application areasmedium-term
Multiple end markets reduce dependence on any single workflow or customer type.
04
Strengthen scientific validationlong-term
Publications and conference exposure help de-risk adoption for OEM and research buyers.
AcouSort is exposed to commercialization risk because its business depends on converting technical validation into...
Commercialization risk
Revenue depends on turning pilots and evaluations into OEM contracts and repeat orders.
- Scope
- Feasibility projects, evaluation kits, and early customer trials.
- Materiality
- high
Technology development risk
The platform must continue to perform reliably across different biological workflows and customer systems.
- Scope
- Diagnostics, cell therapy, and industrial particle-removal use cases.
- Materiality
- high
Competition risk
Customers can choose alternative sample-preparation technologies or in-house solutions.
- Scope
- OEM and research markets.
- Materiality
- medium
Regulatory and quality risk
Medical and life science customers require validated processes and quality systems.
- Scope
- Medical device and cell therapy applications.
- Materiality
- medium
Revenue recognition
Can shift revenue between quarters and affect comparability
Public grants
Can materially affect other income and R&D funding visibility
Capitalized development and patents
Affects asset values, amortization, and reported earnings
Operating leases
Affects operating costs and fixed commitments
Liquidity and accrual estimates
Can influence going-concern assessment and expense accruals
: 11/08/2026